Literature DB >> 9868838

Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russian Federation. Ivanovo Tuberculosis Project Study Group.

G B Migliori1, A G Khomenko, V V Punga, M Ambrosetti, I Danilova, L N Ribka, M Grzemska, H Sawert, M C Raviglione.   

Abstract

Many of the current tuberculosis control programmes in the Russian Federation are based on costly strategies which are underfunded and use long, individualized treatment regimens. This article compares, using a cost-effectiveness analysis, the new WHO strategy implemented in the Ivanovo Oblast (case-finding among symptomatic patients (SCF) and shorter regimens) and the old strategy (active screening of the asymptomatic population (ACF) and longer regimens). The cost per case cured was calculated at different levels of cure rate (45-95%) using three scenarios to describe the new WHO strategy (use of WHO-recommended regimens and three options at increasing rates of admission) and a fourth scenario to describe the old strategy (all patients admitted for the whole treatment and longer regimens). The cost per case detected was determined by calculating the following: yield of the new and old strategy (number of examinations necessary to diagnose one case); cost of the diagnostic process; multiplying yield per cost according to the three scenarios describing the new WHO strategy and a fourth scenario describing the old strategy. In the Ivanovo Oblast the cost per case cured, at 85% cure rate level, ranged from US$ 1197 (new strategy, scenario 1 without food) to US$ 6293 (old strategy, scenario 4) the cost per case detected ranged from US$ 1581 (new strategy, scenario 1) to US$ 4000 (old strategy, scenario 4). Significant savings can result from shifting towards the new WHO strategy. Decision-makers and health administrators should be responsible for re-investing the financial and human resources mobilized by the adoption of cost-effective strategies within the TB control programme.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9868838      PMCID: PMC2305776     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  5 in total

1.  The supply of antituberculosis drugs: price evolution.

Authors:  P Chaulet
Journal:  Tuber Lung Dis       Date:  1995-06

2.  Tuberculosis in Siberia: 1. An epidemiological and microbiological assessment.

Authors:  F Drobniewski; E Tayler; N Ignatenko; J Paul; M Connolly; P Nye; T Lyagoshina; C Besse
Journal:  Tuber Lung Dis       Date:  1996-06

3.  Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.

Authors:  M C Raviglione; D E Snider; A Kochi
Journal:  JAMA       Date:  1995-01-18       Impact factor: 56.272

4.  Tuberculosis trends in eastern Europe and the former USSR.

Authors:  M C Raviglione; H L Rieder; K Styblo; A G Khomenko; K Esteves; A Kochi
Journal:  Tuber Lung Dis       Date:  1994-12

5.  Tuberculosis elimination in the countries of Europe and other industrialized countries.

Authors:  L Clancy; H L Rieder; D A Enarson; S Spinaci
Journal:  Eur Respir J       Date:  1991-11       Impact factor: 16.671

  5 in total
  4 in total

1.  The Effectiveness of Family-Based DOTS versus Professional-Family Mix DOTS in Treating Smears Positive Tuberculosis.

Authors:  Hassan Yekrang Sis; Ali Jannati; Mohammad AsghariJafarabadi; Mohammad Ebrahimi-Kalan; Asghar Taheri; Ahmad Koosha
Journal:  Health Promot Perspect       Date:  2014-07-12

Review 2.  Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward.

Authors:  C D Acosta; A Dadu; A Ramsay; M Dara
Journal:  Public Health Action       Date:  2014-10-21

Review 3.  Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.

Authors:  Yoko V Laurence; Ulla K Griffiths; Anna Vassall
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

4.  Tuberculosis active case finding in Cambodia: a pragmatic, cost-effectiveness comparison of three implementation models.

Authors:  Richard James; Keovathanak Khim; Lydia Boudarene; Joanne Yoong; Chea Phalla; Saly Saint; Pichenda Koeut; Tan Eang Mao; Richard Coker; Mishal Sameer Khan
Journal:  BMC Infect Dis       Date:  2017-08-22       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.